Introduction {#S1}
============

Autophagy is the regulated process that targets unnecessary or dysfunctional cellular components for lysosomal-mediated removal ([@B83]; [@B60]; [@B57]; [@B141]). This process is a crucial recycling mechanism to maintain cellular homeostasis under normal physiological states as well as in disease conditions as it facilitates the orderly degradation of damaged organelles and other cellular components, ([@B68]; [@B48]; [@B57]; [@B31]). The removal of mitochondria through autophagy, a process called mitophagy, is an important element of mitochondrial quality control ([@B143]; [@B93]). This system mediates the selective engulfment of defective or damaged mitochondria by autophagosomes and their subsequent catabolism by lysosomes, preserving overall mitochondrial homeostasis ([@B143]; [@B93]). Significant evidence suggests that mitophagy may be required for adaptation to various stresses, and that dysregulation of mitophagy may contribute to a host of diseases, most notably neurodegenerative conditions such as Parkinson's disease (PD) ([@B87]; [@B38]; [@B65]). The products of two PD-associated genes, the phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1) and the cytosolic E3 ligase Parkin, can sense mitochondrial damage and mediate ubiquitin-dependent mitophagy ([@B87]; [@B143]; [@B98]; [@B139]; [@B93]). Loss-of-function mutations in the regulatory kinase PINK1 and the ubiquitin ligase Parkin have each been identified as a cause for familial, early-onset PD, suggesting that impaired mitophagy may contribute to the loss of dopaminergic neurons that occurs during the PD disease progression ([@B58]; [@B132]; [@B65]; [@B92]; [@B45]). Similarly, the preservation of mitochondrial function through mitophagy is also important for mitochondria-rich and bioenergetically demanding organs such as the heart ([@B85]; [@B10]). Cardiac mitophagy may be required for the myocardium to recover from mitochondrial damage that occurs, for instance, during cardiac hypertrophy or ischemic injury ([@B85]; [@B10]). Evidence suggests a decline in mitophagy may contribute to the myriad of pathological events that occur under metabolic stress or in the elderly heart ([@B26]; [@B66]; [@B67]; [@B85]; [@B113], [@B115]).

Considerable interest has been focused on elucidating the molecular mechanisms of mitophagy, particularly on PINK1/Parkin's ability to catalyze the reaction to ubiquitinate a range of outer mitochondrial membrane (OMM) proteins ([@B87], [@B89]; [@B76]; [@B65]; [@B92]; [@B45]). PINK1 is a mitochondrial-targeted kinase whose stability is regulated, at least in part, by mitochondrial membrane potential (MMP) ([@B87], [@B89]; [@B76]; [@B65]). When MMP is dissipated following mitochondrial damage, PINK1 accumulates on the OMM, where it can phosphorylate ubiquitin attached to OMM and recruit Parkin to impaired mitochondria, thereby triggering its latent E3 ubiquitin ligase activity to ubiquitinate OMM proteins ([@B87], [@B89]; [@B76]; [@B65]). This post-translational tagging of OMM proteins with ubiquitin can serve as a signal to recruit receptors such as optineurin and NDP52, which act as a signal facilitating autophagosomal engulfment of individual damaged mitochondria ([@B53]; [@B65]) ([Figure 1](#F1){ref-type="fig"}). PINK1/Parkin-independent mechanisms can also initiate mitophagy ([@B90]; [@B44]). The proapoptotic Bcl2 family proteins Nix and Bnip3 on the OMM participate in autophagic engulfment of mitochondria through direct interaction with LC3 on autophagosomes ([@B90]; [@B44]) ([Figure 1](#F1){ref-type="fig"}). Newly formed erythrocytes, also known as reticulocytes, eliminate their membrane-bound organelles, including mitochondria, during the course of development ([@B62]; [@B110]). Nix regulated mitophagy may contribute to the rapid and coordinated clearance of mitochondria, also called the programmed mitochondrial degradation, in the process of erythropoiesis, whereas loss of Nix in mice impairs mitochondrial degradation during erythroid maturation ([@B110]; [@B108]). The OMM protein FUNDC1 (FUN14 domain containing 1) can also bind LC3 to recruit autophagosome and promote mitophagy ([@B70]; [@B16]) ([Figure 1](#F1){ref-type="fig"}). FUNDC1-mediated mitophagy may depend on its phosphorylation status regulated by the Unc-51 Like Autophagy Activating Kinase 1 (ULK1), casein kinase 2 (CK2), and PGAM5 phosphatase ([@B15], [@B16]; [@B93]). Recent progress has demonstrated a crucial role for the inner mitochondrial membrane (IMM) proteins in mitophagy regulation. Notably, IMM protein prohibitin 2 (PHB2), a component of the mitochondrial prohibitin complex, may serve as a mitochondrial receptor for mitophagy upon mitochondrial depolarization ([@B135]).

![Mitophagy is a critical mechanism to maintain mitochondrial quality in the brain and heart. Mitophagy can be regulated by multiple mechanistically distinct pathways: the PINK1/Parkin dependent mitophagy, which is mediated by mitophagy receptors such as optineurin and NDP52; BNIP3 and NIX regulated mitophagy to facilitate autophagic engulfment of mitochondria; and FUNDC1 mediated mitophagy. Manipulating autophagy/mitophagy activity may preserve mitochondrial function and serve as a novel therapeutic strategy, such as spermidine ([@B26]), rapamycin ([@B111]; [@B140]; [@B20]; [@B101]), nicotinamide mononucleotide ([@B30]), urolithin A ([@B105]; [@B30]), actinonin ([@B30]), and Tat-Beclin 1 ([@B116]; [@B115]).](fcell-08-00294-g001){#F1}

While there has been considerable mechanistic insight into the regulatory pathways of mitophagy, investigation into the role of mitophagy in healthy and disease conditions has only just begun. Mouse tissue analysis has revealed a variation in basal mitophagy levels ([@B125]; [@B79]), which might be required for continuous mitochondrial housekeeping. Stressed-induced mitophagy has been implicated in a tissue's ability to recover from mitochondrial damage, as well as appropriately responding to metabolic and bioenergetic stressors ([@B124]; [@B10]; [@B93]). In energetically demanding tissues such as the heart and the brain, the mitophagic removal might require exquisite regulatory mechanisms, which merit further investigation. Additionally, recent studies have demonstrated an essential role for programmed mitophagy that directs the developmental metabolic transitioning of cardiac mitochondria ([@B42]). In summation, the preservation of mitochondrial function is crucial for all tissues, but it is undoubtedly critical for bioenergetically demanding organs such as the brain and the heart. Here, we will review how mitophagy represents a major pathway to help sustain mitochondrial quality and how alterations in mitophagy can contribute significantly to both neurodegenerative and cardiovascular diseases ([Figure 1](#F1){ref-type="fig"}). The ability to genetically and pharmacologically modulate mitophagic flux may provide considerable insight into mitochondria related disease mechanisms and allow for the development of novel therapeutic approaches.

Mitophagy in Neurodegenerative Diseases {#S2}
=======================================

There is a growing appreciation regarding the critical role of altered mitochondrial function in the pathogenesis of neurodegenerative diseases ([@B132]; [@B143]; [@B123]; [@B50]; [@B93]). Selective identification and removal of damaged or dysfunctional mitochondria through mitophagy is thought to be an effective mechanism in maintaining neuronal mitochondrial homeostasis ([@B51]; [@B50]; [@B79]). Evidence suggests a decline in mitophagy might contribute to many neurodegenerative diseases ([@B13]; [@B7]; [@B32]; [@B30]).

Attention to mitophagy has been augmented by its link to genes related to inherited forms of early-onset PD ([@B58]; [@B132]; [@B65]; [@B6]; [@B118]). PD is one of the most common neurodegenerative disorders characterized by a series of motor impairments including tremors, rigidity, bradykinesia (slowness of movement), and postural instability (poor balance), which are caused by the progressive loss of dopaminergic neurons in the substantia nigra of the brain ([@B1]). Although medical and surgical treatments may provide symptomatic relief, there is no cure for PD ([@B21]; [@B88]; [@B36]; [@B11]; [@B103]; [@B13]; [@B47]; [@B91]; [@B35]; [@B1]). Identification of genes mutated in monogenic forms of PD has provided valuable insight into the etiology of the disease ([@B88]; [@B13]; [@B35]; [@B1]). Specifically, mutations or variants of PINK1 and Parkin have been found in the inherited forms of early-onset PD's patient ([@B58]; [@B132]; [@B65]; [@B6]; [@B118]). Biochemical and genetic studies reveal the products of these two genes, PINK1 and Parkin, normally function within the same genetic pathway to govern mitochondrial quality control ([@B65]; [@B6]; [@B118]). PINK1 can detect and accumulate on the damaged mitochondria, which results in activation of Parkin's E3 ubiquitin ligase activity and recruitment of Parkin to the dysfunctional mitochondrion ([@B87]; [@B76]; [@B46]; [@B65]). Parkin then ubiquitinates OMM proteins to promote mitophagy ([@B46]; [@B65]; [@B118]). The realization that PINK1 and parkin can work together in the same pathway to coordinate mitophagy strengthens the notion that mitophagy may play an important role in PD ([@B46]; [@B65]; [@B118]). Therefore, the biochemical mechanisms of PINK1/Parkin mediated mitophagy, along with their roles in various models of PD, have been studied extensively over the past 10 years. While the generation of Parkin and PINK1 mutant flies has elucidated the functions of these genes in regulating mitochondrial integrity ([@B18]; [@B96]; [@B93]), PINK1 and Parkin knockout mouse models poorly recapitulate dopamine neurodegeneration and the pathophysiology of human PD ([@B41]; [@B54]; [@B59]; [@B5]; [@B46]; [@B65]; [@B118]). A significant portion of basal mitophagy occurs within the PD-relevant dopamine neurons of the substantia nigra pars compacta and in microglia, indicating a critical role of mitophagy in these cells under physiological conditions ([@B79]). However, PINK1 or Parkin does not appear to influence basal mitophagy ([@B78], [@B79]). This data suggests that the precise role of PINK1/Parkin under physiological conditions remains to be defined. The pathophysiological basis of the cross-regulation between various mitochondrial quality control pathways will be of prime importance in understanding how mitophagy occurs and how it relates to PD progression.

Insight into the mechanisms underlying mitophagy and the importance of mitochondrial quality control have extended to other common neurodegenerative diseases associated with mitochondrial dysfunction such as Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) ([@B131]; [@B142]; [@B92]; [@B14]; [@B29]). Impaired mitophagy is closely related to AD, another important age-related neurodegenerative disease ([@B32]; [@B30]). AD is an irreversible, progressive brain disorder, characterized by cognitive defects and a progressive decline in memory ([@B32]; [@B30]). Like PD, the symptoms of AD are related to the loss of important neurons in certain areas of the brain, including the hippocampus, entorhinal cortex, temporal lobe, parietal lobe, and frontal lobe ([@B32]; [@B30]). Although the etiology of AD remains unclear, the accumulation of intracellular hyperphosphorylated tau (p-tau) and extracellular amyloid β-peptide (Aβ) have been identified in the onset and progression of the disease ([@B9]; [@B32]; [@B30]; [@B127]). Aβ and p-tau pathologies can contribute to mitochondrial defects, and in AD, neurons may display mitochondrial dysfunction and a bioenergetic deficit ([@B77]; [@B56]; [@B30]). Impairment of mitochondrial function has been identified in the brain tissues of AD mouse models, as well as in human samples of both sporadic and familial types of AD ([@B72]; [@B30]). Mitochondria dysfunction can accelerate Aβ deposit at the cellular level and contribute to hyperphosphorylation of tau in neurons ([@B27]; [@B77]; [@B56]; [@B30]). Accumulating evidence demonstrates that a decline in mitophagy may contribute to impaired mitochondrial homeostasis in AD ([@B32]; [@B14]; [@B30]). Under AD-linked pathophysiological conditions, Parkin-mediated mitophagy is altered in AD mutant neurons and in AD patient brains ([@B142]). Inadequate mitophagy capacity may contribute to the aberrant accumulation of dysfunctional mitochondria in AD-affected neurons ([@B142]; [@B32]; [@B14]; [@B30]). Interestingly, using postmortem human AD brain samples, induced pluripotent stem cell-derived human AD neurons, and a set of AD animal models, a recent study demonstrates defective mitophagy in AD ([@B30]). Of note, pharmacological restoration of mitophagy ameliorates memory loss in both *Caenorhabditis elegans* and mouse models of AD ([@B30]). Thus, targeting the mitochondrial quality control system may provide a novel therapeutic strategy for AD.

Mitochondrial dysfunction also has been implicated in the pathology of HD, another progressive neurodegenerative disease caused by a genetic mutation in the huntingtin gene ([@B114]; [@B51]). In HD, the pathological expansion of CAG trinucleotide repeat encoding a polyglutamine (polyQ) tract in the amino-terminal region of the Huntingtin protein results in an abnormal polyglutamine stretch and in accumulation of polyQ-expanded HTT ([@B77]; [@B121]; [@B74]). Due to the loss of GABAergic neurons in the basal ganglia HD is characterized by motor dysfunction, psychiatric disturbance, and a decline in cognition ([@B104]). The mutant huntingtin protein may affect a wide range of cellular pathways and functions, including transcriptional regulation, axonal trafficking of vesicles, mitochondrial function, ubiquitin-mediated proteolysis, and the autophagic systems ([@B73]; [@B37]; [@B131]; [@B137]; [@B74]). Damaged mitochondria and impaired mitophagy are closely related to neuronal death and disease progression in HD ([@B77]; [@B121]; [@B74]). Mutant HTT can bind the mitochondrial fission GTPase dynamin−related protein−1, and perturb mitochondrial dynamics in HD, leading to the accumulation of damaged mitochondria and increased reactive oxygen species (ROS) ([@B114]; [@B121]). Research has indicated that mutant HTT mediated transcriptional dysregulation of autophagy-related genes, cargo recognition failure of autophagosomes, and impaired trafficking of lysosomes contribute to inefficient autophagy in HD ([@B75]). Additionally, recent studies demonstrate that mutant HTT can interact with the Ser/Thr-kinase ULK1 and p62/SQTM12 ([@B69]; [@B136]), thereby potentially regulating mitophagy. Furthermore, expression of mutant HTT with expanded polyglutamine repeats may alter GAPDH-mediated mitophagy, thus contributing to the pathology of HD ([@B51]). Using mt-Keima mice to measure *in vivo* mitophagic flux, markedly reduced levels of mitophagy have been observed in mutant HTT-expressing mice ([@B125]). Therefore, the presence of the expanded polyQ tract can affect the neuronal mitophagy, and consequently promote mitochondrial dysfunction, contributing to disease progression in HD.

Defects in mitophagy appear to have significance with regards to familial ALS, also known as motor neuron disease or Lou Gehrig's disease ([@B29]). ALS is characterized by a progressive degeneration of motor neurons in the spinal cord and brain ([@B29]). Several of the ALS-associated genes have been functionally implicated in autophagy or the mitophagy process ([@B29]). These include VCP, encoding valosin-containing protein, implicated in autophagy ([@B12]) and the maintenance of lysosomal function ([@B95]), as well as the noncoding sequence of the C9ORF72 gene, mutations of which account for approximately 40% of familial ALS ([@B22]; [@B102]; [@B33]). C9ORF72 may regulate ULK1 and may function in the regulation of lysosomal fusion or function ([@B22]; [@B102]; [@B33]). Mutations in the serine/threonine kinase Tank-binding kinase 1 (TBK1) and the autophagy receptor optineurin (OPTN) are associated with ALS ([@B84]). ALS-linked mutations in OPTN and TBK1 can interfere with mitophagy suggesting, an inefficient turnover of damaged mitochondria may represent a key pathophysiological mechanism contributing to neurodegenerative disease. The TBK1-OPTN axis can target damaged mitochondria and promote autophagosome formation around mitochondria triggering mitophagy ([@B65]; [@B92]; [@B45]). Inhibition of TBK1 or expression of ALS-linked TBK1 mutant can block efficient autophagosome formation ([@B84]). In neurons, an ALS-associated mutation in OPTN is sufficient to disrupt mitochondrial function under basal conditions, due to the slow kinetics of mitophagy ([@B28]). Mutant Cu/Zn superoxide dismutase (SOD1) also causes alterations of mitochondrial function in ALS ([@B94]). Interestingly, a recent study demonstrates that Parkin genetic ablation slows down motor neuron demise, delays ALS disease progression, and thus extends the lifespan of the SOD1−G93A mutant mice ([@B94]). Therefore, understanding the molecular basis for autophagy and mitophagy in familial ALS should provide considerable insight into the disease-causing mechanisms involved in ALS pathogenesis, and may lead to the development of more effective therapeutic approaches for ALS.

Mitochondrial defects have been linked to neuronal dysfunction and the pathogenesis of neurodegenerative diseases. In neurons, mitophagy serves as a major pathway required for the preservation of mitochondrial function. Mitophagy deficit's role in neurodegenerative diseases has only been recently recognized despite the significant advancements in understanding the molecular and the cellular mechanisms that govern mitophagy. Given the fact that neurons have an exceptionally high demand for ATP, the quality control of mitochondria is essential for neuronal functions. The same can be said for cardiomyocytes, in which mitochondria occupy approximately one-third of the cell volume ([@B109]; [@B85]; [@B3]). Therefore, defective mitophagy may impair mitochondrial homeostasis and can be particularly detrimental for these terminally differentiated cells such as the postmitotic neurons and cardiomyocytes ([@B143]; [@B10]; [@B93]). Interestingly, researchers recently have noticed a link between various cardiovascular abnormalities and neurodegenerative diseases. For instance, Aβ aggregations have been reported to be present in the hearts of patients with idiopathic dilated cardiomyopathy ([@B40]). And recent studies have demonstrated compromised myocardial function and intramyocardial deposits of Aβ in AD patients ([@B130]). Likewise, clinical studies on HD patients at various stages of disease progression have revealed a high incidence of cardiovascular events ([@B80]; [@B122]; [@B61]). Although neurons and cardiomyocytes vary a lot in their structure and function, these findings depict a possible biological framework linking neurodegenerative diseases to cardiovascular risks. However, evidence of a possible role that mitochondria play calls for further analysis of this connection.

Mitophagy in Cardiovascular Disease {#S3}
===================================

The heart demands a substantial amount of energy to fuel myocardial contraction and is subsequently rich in mitochondria ([@B85]; [@B3]). The cardiac mitochondria account for ∼30% of myocellular volume and possess the capacity to use multiple metabolic substrates to generate ATP under a wide range of physiological and pathological conditions ([@B109]; [@B85]; [@B3]). Also, mitochondria are essential organelles in the regulation of metabolic substrate utilization, cell death, calcium storage, and ROS levels ([@B133]; [@B82]; [@B124]). Mitophagy plays a critical role in preserving mitochondrial quality in normal cardiovascular physiology and in pathological circumstances. During the early perinatal period, changes in oxygen and nutrient availability catalyze a switch in cardiac substrate preference from glucose to fatty acids ([@B42]; [@B25]). Recent studies have demonstrated an essential role for mitophagy in the normal perinatal transformation of myocardial metabolism ([@B42]). During cardiac stress and injury, mitophagy increases to help clear damaged mitochondria, as well as prevent oxidative damage and cell death ([@B49]; [@B63]). In response to pressure overload-induced mitochondrial dysfunction, mitophagy can be activated dynamically and play a protective role against heart failure ([@B115]). Over the past decade, significant progress has been made in understanding of the physiological and pathological roles of cardiac mitophagy ([@B5]; [@B85]; [@B128]; [@B10]; [@B134]).

The functional significance of cardiac mitophagy has been revealed by analyzing loss-of-function mouse models of autophagy achieved by cardiac-specific ATG5 or ATG7 ablation ([@B86]; [@B126]). In most cases, a functional macroautophagy machinery is needed for selective removal of damaged mitochondria, while ATG5 and ATG7 are essential genes for optimal autophagic responses ([@B143]; [@B93]). Mice with temporally controlled cardiomyocyte-specific deletion of ATG5 exhibit left ventricular dilatation, with an accumulation of damaged mitochondria in the heart ([@B86]; [@B126]). ATG7-dependent activation of cardiac mitophagy recently has been reported to protect the myocardium from the metabolic stress of a high-fat diet ([@B129]). Therefore, interventions designed to stimulate autophagy in the cardiovascular system may prevent the accumulation of damaged mitochondria under cardiac stress and exhibit potential cardioprotective effects. Eisenberg et al. reported that the polyamine spermidine, delivered as a dietary supplement, can enhance cardiac autophagy/mitophagy, ameliorate age-related cardiac hypertrophy and preserve diastolic function in older mice ([@B26]). Interestingly, a functional autophagy system in cardiomyocytes is required for the cardioprotective effects of spermidine ([@B26]). Furthermore, genetic studies have demonstrated the key role of the Ser/Thr-kinase ULK1 in mediating mitophagy and early autophagosome formation ([@B138]). ULK1-regulated mitophagy is activated in response to energetic stress and may play an essential role in preserving mitochondrial function following myocardial ischemia ([@B106]).

The impact of PINK1 and Parkin has been extended in the cardiovascular system. In Drosophila models, genetic deletion of either PINK1 or Parkin can lead to mitochondrial dysfunction and poor cardiac contractibility ([@B43]; [@B4]). Genetic deletion of PINK1 in mice results in cardiac hypertrophy and progressive cardiac dysfunction ([@B5]). These mice also exhibit increased infarct size in response to ischemia-reperfusion injury ([@B117]). Furthermore, PINK1-mediated mitochondrial quality control could be important during acute cardiac mitochondria stress following exhaustive exercise ([@B118]). Mice with Parkin deletion demonstrate normal baseline cardiac phenotypes ([@B63]; [@B99]), but exhibit an increased sensitivity to stress conditions from myocardial infarction (MI) or cardiac aging, along with a decline in cardiac mitophagy and accumulation of dysfunctional mitochondria ([@B49]; [@B63]). It is worth mentioning those cardiac abnormalities, such as cardiomyopathy, arrhythmia, and sudden cardiac death, are still under investigation, though rare may occur in PD patients ([@B112]). Therefore, under specific cardiac pathophysiological circumstances, PINK1 and Parkin may serve as a regulatory mechanism of mitophagy in the heart. Additional mitochondrial quality control pathways regulated by NIX and BNIP3 ([@B24]), FUNDC1 ([@B144]; [@B64]) or general autophagy may compensate for the loss of PINK1/Parkin-mediated mitophagy. The functional significance of PINK1 and Parkin may require further investigation.

Recent progress also has linked mitophagy to the processes of mitochondrial dynamism, fission and fusion ([@B143]; [@B93]; [@B97]). Cell biological observations suggest that a group of fission and fusion proteins regulate mitochondrial morphology depending on the metabolic status ([@B82]). Mitofusins, MFN1, and MFN2, as well as optic atrophy protein 1 (OPA1) promote the mitochondrial fusion ([@B82]), whereas the dynamin-related protein 1 (DRP1) mediates mitochondrial fission ([@B34]; [@B81], [@B82]) ([Figure 1](#F1){ref-type="fig"}). MFN2 can be phosphorylated by the PINK1 kinase on the OMM, which facilitates Parkin translocation to promote mitophagy ([@B17]). MFN2 deletion in mouse hearts disrupts mitophagic flux independent of its activity in fission/fusion regulation ([@B119]). Mitochondrial fission, on the other hand, allows for mitochondrial fragmentation and has been suggested to regulate mitophagy ([@B100]; [@B81], [@B82]). Several studies have demonstrated that genetic manipulation of DRP1 in mouse hearts can alter myocardial mitochondrial function and mitophagy ([@B55]; [@B120]; [@B115]). Cardiomyocyte-specific homozygous deletion of DRP1 suppresses mitophagy, and leads to dilated cardiomyopathy in mouse models, while the heterozygous DRP1 knockout mice are more susceptible to ischemia/reperfusion injury ([@B52]). Furthermore, in the murine heart, DRP1 may mediate mitophagy in response to mitochondrial dysfunction under pressure overload, while haploinsufficiency of DRP1 exacerbates the progression of heart failure ([@B115]). The particular role for fission/fusion mediated mitophagy in healthy and in diseased hearts, as well as how PINK1 and Parkin participate in the regulatory mechanisms associated with mitochondrial fission/fusion is still under investigation ([@B55]; [@B120]).

Cardiovascular disease imposes a huge burden worldwide, in terms of mortality, morbidity, and healthcare costs ([@B23]; [@B2]). Despite significant progress in understanding the pathophysiology of the disease, the prevalence of cardiovascular disease and its mortality rates remain high ([@B23]; [@B2]). Although preclinical studies suggest the potential benefit of mitochondria-targeted therapies in cardiovascular disease, it remains to be established whether the preservation of mitochondrial function through modulating mitophagy will result in improved clinical outcomes in patients ([@B85]; [@B10]). A better understanding of the regulatory mechanisms of mitophagy in the heart and its pathophysiologic role in cardiovascular disease are needed to develop effective mitophagy-targeted therapeutic agents and translate this innovative treatment strategy.

Perspectives {#S4}
============

Mitophagy serves as a critical mechanism to eliminate damaged mitochondria and is regulated by multiple mechanistically distinct pathways ([@B143]; [@B93]). Cellular level studies have provided valuable insight into the signaling pathways regulating mitophagy, as well as mapping out how and when mitophagy occurs in a wide range of physiological and pathological conditions to counter cellular stressors such as ROS or damaged mitochondria ([@B143]; [@B10]; [@B93]). A better understanding of mitochondrial turnover mechanisms, with an improved focus on how these pathways might contribute to disease pathogenesis, should allow for the development of more efficient strategies to battle numerous pathological conditions associated with mitochondrial dysfunction.

Mitophagy is an important element of overall mitochondrial quality control. Defective mitophagy is thought to contribute to normal aging as well as various neurodegenerative and cardiovascular diseases ([@B143]; [@B124]). In fact, aging by itself is a major risk factor for the pathophysiology of cardiovascular and neurodegenerative diseases ([@B26]; [@B32]; [@B8]). Increasing evidence suggests that mitophagy failure accelerates aging ([@B26]; [@B124]; [@B32]; [@B8]). Interestingly, a marked age-dependent decline in mitophagy has been observed in the hippocampus of the mouse brain ([@B125]), an area where new memory and learning are encoded. Similar effects have been noted in mouse models of HD ([@B125]). This strengthens the hypothesis that mitophagy might regulate neuronal homeostasis and that a decline in mitophagy might predispose to age-dependent neurodegeneration. Age-related mitochondrial function deterioration is underlined as a key feature of other diseases, such as obesity, diabetes, and cancer ([@B26]; [@B124]; [@B32]; [@B8]). Therefore, maintaining a healthy mitochondrial network via functional mitophagy may serve as an attractive therapeutic strategy in the treatment of a wide range of age-related diseases, and potentially regulate longevity.

The emergence of nutritional and pharmacological interventions to modulate autophagy/mitophagy and to serve as a potential therapeutic model is quite encouraging. Accumulation of ubiquitinated OMM proteins has been proposed to act as a signal for selective mitophagy ([@B143]; [@B93]). As described above, ubiquitination of mitochondrial proteins is positively regulated, in part, by the E3 ubiquitin ligase, Parkin ([@B87], [@B89]; [@B76]; [@B143]). In contrast, removal of ubiquitin is achieved by the action of resident mitochondrial deubiquitinases, most notably USP30, thereby acting to antagonize mitophagy ([@B7]; [@B19]; [@B6]; [@B39]). Inhibition of USP30 enzyme activity may provide an unambiguous avenue to pursue the role of mitophagy as a therapeutic target. In addition, the natural polyamine spermidine can preserve cardiac diastolic function in older mice by inducing mitophagy ([@B26]). Inhibitors of mTOR can induce autophagy, and protect against various cardiac pathologies, and prolong lifespan in diverse species ([@B111]; [@B140]; [@B20]; [@B101]). Recently, three promising candidates that may stimulate and reinvigorate mitophagy process have been demonstrated to reduce the accumulation of amyloid-beta and phosphorylated tau in Alzheimer's mouse brains ([@B30]). These compounds, including nicotinamide mononucleotide, urolithin A, and actinonin, can improve symptoms of AD and dementia symptoms in preclinical models ([@B30]). In addition, Tat-Beclin 1 peptide, derived from a region of the autophagy protein, beclin 1, can promote autophagy/mitophagy and improve mitochondrial function in heart failure animal models ([@B115]). Therefore, identifying more efficient and specific agents that can modulate the clearance of defective mitochondria are likely to have significant therapeutic benefits.

Recent advances have greatly expanded our knowledge of how mitophagy functions in health and disease. The magnitude and kinetics of mitophagy in various disease conditions, however, remains to be elucidated. Although mitophagy has many potential benefits, under certain conditions, uncontrolled or overactive mitophagy may disrupt organelles' integrity and may prove detrimental to cell health ([@B71]; [@B107]). Therefore, it is essential to elucidate how mitophagy collaborates with other cellular processes, such as autophagy, mitochondrial fission/fusion, and mitochondrial biogenesis to restore unhealthy mitochondria and maintain overall mitochondrial homeostasis. Furthermore, it is critical to determine when and to what extent manipulating mitophagy activity may regulate and keep mitochondria in health to prevent disease progression.
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